2016 Fiscal Year Final Research Report
Development of novel immunotherapy for chronic inflammation by MDSC
| Project/Area Number |
15K15310
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Cardiovascular medicine
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Keywords | ワクチン / 免疫治療 |
|---|
| Outline of Final Research Achievements |
MRP8/14 (S100A8/A9) is highly expressed in MDSC cells and induces inframmatory cytokines. To examine the potential role of MRP8/14, we developed a peptide vaccine which is composed of KLH and a B-cell epitope of MRP8/14. After immuinization, anti- MRP8/14 antibody titer was increased and sustained for more than two months after injection of vaccine. Importantly, it could suppress thrombus formation in middle cerebral arteries in mice for at least 2 months without affecting hemostatic parameters. Although S100A9 forms heterodimer with S100A8, the vaccine for S100A8 showed no effects. Thus, S100A9 antithrombotic vaccine might be a novel strategy to prevent recurrent strokes in non-adherent patients.
|
| Free Research Field |
循環器内科、免疫治療
|
